<DOC>
	<DOCNO>NCT00944216</DOCNO>
	<brief_summary>Keratosis pilaris ( KP ) benign skin condition often frustrating patient treat physician . The investigator interest see study product effective treat moderate severe KP .</brief_summary>
	<brief_title>Efficacy Safety Salkera Emollient Foam Treatment Moderate Severe Keratosis Pilaris , Prospective Study</brief_title>
	<detailed_description>Keratosis pilaris ( KP ) benign , inherit skin disorder present group , rough , horny follicular papule . It estimate 40-50 % adult population 50-80 % adolescent suffer KP . Both men woman affect , possible female predominance . It note worldwide show racial predilection . Most patient KP actually unaware condition design medical term . Although clear etiology identify , KP sometimes associate skin condition icththyosis vulgaris , xerosis atopic dermatitis . Many patient KP never seek medical attention since asymptomatic . However , KP create significant cosmetic concern case . It also become symptomatic especially inflammatory lesion present . There gold standard treatment KP . Prevention excessive dryness skin continue moisturization use currently standard care . Many topical agent tretinoin , ammonium lactate lotion , urea cream , tazarotene , adapalene , tacrolimus , alpha hydroxy acid salicylic acid use variable result . Sometimes topical corticosteroid use , especially inflammation present . In general , KP treatment need continuous complete clearance may possible . Salkera emollient foam keratolytic foam contain 6 % salicylic acid aqueous base emollient foam vehicle . It different salicylic contain topical product show produce desquamation stratum corneum effect qualitative quantitative change structure viable dermis . In addition , also contain aloe vera anti-oxidants help sooth skin . Salkera emollient foam use treat several hyperkeratotic skin disorder KP , psoriasis , keratosis palmaris/plantaris , verruca , icthyoses pityriasis rubra pilaris . However , publish study assess efficacy safety Salkera emollient foam treat moderate severe KP . This prospective single center pilot study design ass efficacy safety Salkera emollient foam treat moderate severe KP . Patients ' cosmetic acceptance product also assess . In addition , study also design develop validate outcome measure assess KP severity use future KP clinical trial .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Abnormalities , Multiple</mesh_term>
	<mesh_term>Darier Disease</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<mesh_term>Emollients</mesh_term>
	<criteria>Subject willing able give inform consent . Subject willing able participate study outpatient willing comply study requirement . Subject 18 year age old . Subject KP 2 4 extremity . For assessed extremity , subject least moderate severity ( â‰¥ 3 ) Investigator Site Assessment KP Severity . For assessed extremity , subject aggregate score least 6 Investigator Assessment Erythema , Roughness Scaling . If subject female childbearing potential , subject negative urine pregnancy test screening ( week 0 ) . If female , subject either postmenopausal &gt; 2 year , surgically sterile ( hysterectomy bilateral tubal ligation ) , practice one form birth control ( abstinence , oral contraceptive , estrogen patch , implant contraception , injectable contraception , IUD , diaphragm , condom , sponge , spermicide , vasectomy partner ) . Female subject continue practice birth control 1 month completion study . Subject evidence clinically significant , unstable poorly control medical condition determine investigators/subinvestigators . Subject active skin infection , atopic dermatitis skin disease interfere clinical assessment KP . Subject known allergy ingredient study medication . Subject use follow topical therapy KP lesion within last two week : topical corticosteroid , tretinoin , tazarotene , adapalene , salicylic acid , alphahydroxy acid , urea and/or ammonium lactate lotion . Subject treat UVB therapy last two week . Subject receive systemic antibiotic , steroid , tacrolimus , tretinoin , isotretinoin and/or PUVA within last 4 week . Female subject pregnant ( positive urine pregnancy test ) , breastfeed consider become pregnant study period . Subject currently participate another clinical trial complete clinical trial within last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>keratosis pilaris</keyword>
</DOC>